CA2774173A1 - Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury - Google Patents

Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury Download PDF

Info

Publication number
CA2774173A1
CA2774173A1 CA2774173A CA2774173A CA2774173A1 CA 2774173 A1 CA2774173 A1 CA 2774173A1 CA 2774173 A CA2774173 A CA 2774173A CA 2774173 A CA2774173 A CA 2774173A CA 2774173 A1 CA2774173 A1 CA 2774173A1
Authority
CA
Canada
Prior art keywords
biomarker
gfap
mir
tau
terminal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2774173A
Other languages
English (en)
French (fr)
Inventor
Kevin Ka-Wang Wang
Zhiqun Zhang
Ming Cheng Liu
Ronald L. Hayes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Banyan Biomarkers Inc
Original Assignee
Banyan Biomarkers Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43733138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2774173(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Banyan Biomarkers Inc filed Critical Banyan Biomarkers Inc
Publication of CA2774173A1 publication Critical patent/CA2774173A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
CA2774173A 2009-09-14 2010-09-14 Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury Abandoned CA2774173A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US24212309P 2009-09-14 2009-09-14
US61/242,123 2009-09-14
US35450410P 2010-06-14 2010-06-14
US61/354,504 2010-06-14
US35577910P 2010-06-17 2010-06-17
US61/355,779 2010-06-17
US38015810P 2010-09-03 2010-09-03
US61/380,158 2010-09-03
PCT/US2010/048789 WO2011032155A2 (en) 2009-09-14 2010-09-14 Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury

Publications (1)

Publication Number Publication Date
CA2774173A1 true CA2774173A1 (en) 2011-03-17

Family

ID=43733138

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2774173A Abandoned CA2774173A1 (en) 2009-09-14 2010-09-14 Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury

Country Status (8)

Country Link
US (3) US20130022982A1 (enExample)
EP (1) EP2478360B1 (enExample)
JP (3) JP5909447B2 (enExample)
AU (2) AU2010291933B2 (enExample)
CA (1) CA2774173A1 (enExample)
ES (1) ES2687469T3 (enExample)
HU (1) HUE040281T2 (enExample)
WO (1) WO2011032155A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103656685A (zh) * 2014-01-10 2014-03-26 厦门大学 microRNA-219在制备抗癫痫药物中的应用

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8492107B2 (en) 2004-04-15 2013-07-23 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
CA2733990C (en) 2008-08-11 2018-12-11 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
US20170315136A9 (en) * 2009-06-19 2017-11-02 Banyan Biomarkers, Inc. Biomarker assay of neurological condition
CA2766057A1 (en) * 2009-06-19 2010-12-23 Banyan Biomarkers, Inc. Biomarker assay of neurological condition
WO2011032155A2 (en) 2009-09-14 2011-03-17 Banyan Biomarkers, Inc. Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury
WO2012045324A1 (en) * 2010-10-07 2012-04-12 Mediagnost Gesellschaft Fur Forschung Und Herstellung Von Diagnostika Gmbh Method for detecting a parkinson's disease and test system
WO2012051519A2 (en) 2010-10-14 2012-04-19 The Johns Hopkins University Biomarkers of brain injury
DE102011011280A1 (de) * 2011-02-15 2012-08-16 Euroimmun Medizinische Labordiagnostika Ag Diagnosekit sowie ein Verfahren zur Untersuchung einer menschlichen Patientenprobe auf das Vorhandensein von Neuromyelitis-optica-spezifischen Antikörpern
US20140302532A1 (en) 2011-04-12 2014-10-09 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
GB201111361D0 (en) * 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
US20140206777A1 (en) * 2011-08-16 2014-07-24 Rosetta Genomics Ltd. Methods and compositions for diagnosis of alzheimer's disease
JP6392202B2 (ja) 2012-03-13 2018-09-19 ザ・ジョンズ・ホプキンス・ユニバーシティ 脳損傷または神経変性のバイオマーカーとしてのシトルリン化脳および神経タンパク質
WO2013173596A1 (en) * 2012-05-16 2013-11-21 Trustees Of Boston University Chronic traumatic encephalopathy in blast-exposed individuals
SG10201913370PA (en) * 2012-07-03 2020-03-30 Univ Washington Antibodies to tau
US9856532B2 (en) * 2012-09-07 2018-01-02 Institute For Systems Biology Markers and methods for detecting posttraumatic stress disorder (PTSD)
US20140073524A1 (en) * 2012-09-07 2014-03-13 Institute For Systems Biology Markers and methods for detecting posttraumatic stress disorder (ptsd)
WO2015009907A1 (en) 2013-07-17 2015-01-22 The Johns Hopkins University A multi-protein biomarker assay for brain injury detection and outcome
GB201319761D0 (en) * 2013-11-08 2013-12-25 Nordic Bioscience As Biomarkers of disease progression
WO2015134551A1 (en) * 2014-03-03 2015-09-11 Banyan Biomarkers, Inc. Micro rna markers for diagnosis of a neurological condition
US9605315B2 (en) * 2014-03-26 2017-03-28 The University Of Montana Detection of traumatic brain injury
WO2015157300A1 (en) * 2014-04-07 2015-10-15 Iron Horse Diagnostics, Inc Traumatic brain injury and neurodegenerative biomarkers, methods, and systems
CA2948478A1 (en) * 2014-04-08 2015-10-15 University Of Florida Research Foundation, Incorporated Protein biomarkers for acute, subacute and chronic traumatic injuries of the central nervous system
WO2015160391A1 (en) * 2014-04-15 2015-10-22 The Government Of The United States, As Represented By The Secretary Of The Army, On Behalf Of Walter Reed Army Institute Of Research Diagnosis and treatment of tauopathy and chronic traumatic encephalopathy
WO2015196191A1 (en) * 2014-06-20 2015-12-23 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Microrna biomarkers for traumatic brain injury and methods of use thereof
WO2016049429A1 (en) * 2014-09-26 2016-03-31 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Microrna biomarkers for posttraumatic stress disorder and methods of use thereof
CN107003317B (zh) * 2014-10-06 2019-04-19 日内瓦大学 生物标记及其在脑损伤中的应用
CN107533048A (zh) * 2015-02-05 2018-01-02 美国免疫阵列公司 用于诊断脑损伤或神经退行性变的方法和组合物
WO2016205730A1 (en) * 2015-06-18 2016-12-22 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Citrullinated proteins and their breakdown products as tbi biomarkers
CA2993989A1 (en) * 2015-07-29 2017-02-02 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Microrna biomarkers for traumatic brain injury and methods of use thereof
US11053545B2 (en) 2015-09-08 2021-07-06 The Translational Genomics Research Institute Biomarkers and methods of diagnosing and prognosing mild traumatic brain injuries
WO2017087726A1 (en) * 2015-11-18 2017-05-26 Dignity Health Methods of diagnosing epilepsy
GB201603967D0 (en) * 2016-03-08 2016-04-20 Univ Birmingham Biomarkers of traumatic brain injury
US10865372B2 (en) * 2016-04-28 2020-12-15 The Foundation For The Promotion Of Industrial Science Neuron cultivation device, neuron cultivating method, cultivated neuron, analysis and identification of protein in axon bundle, and usage of cultivated neuron
US20190137490A1 (en) * 2016-05-06 2019-05-09 Duke University Methods and kits for diagnosing and treating nervous system disease or injury
US11402379B2 (en) 2016-09-09 2022-08-02 Mayo Foundation For Medical Education And Research Methods and materials for identifying and treating autoimmune GFAP astrocytopathy
IT201600093825A1 (it) * 2016-09-19 2018-03-19 Fondazione St Italiano Tecnologia Composizione farmaceutica di miRNA e suoi usi terapeutici.
JP2020500508A (ja) 2016-10-28 2020-01-16 バンヤン・バイオマーカーズ・インコーポレーテッド ユビキチンｃ末端ヒドロラーゼｌ１（ｕｃｈ−ｌ１）およびグリア線維酸性タンパク質（ｇｆａｐ）に対する抗体および関連する方法
EP3545311B1 (en) * 2016-11-23 2024-03-27 Randox Laboratories Ltd Gfap derivatives for stroke diagnostics
WO2018148294A2 (en) * 2017-02-07 2018-08-16 Bioregency, Inc. S100β AND ISOFORMS FOR DETECTION OF NEUROLOGICAL CONDITIONS
JP2020508054A (ja) 2017-02-17 2020-03-19 デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 抗タウ抗体及びその使用方法
CA3052513A1 (en) 2017-03-23 2018-09-27 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
WO2018190365A1 (ja) * 2017-04-12 2018-10-18 国立大学法人九州大学 神経障害性疼痛マーカー及びその使用
ES3055047T3 (en) 2017-04-15 2026-02-09 Abbott Lab Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
CN110603449A (zh) 2017-04-28 2019-12-20 雅培实验室 用同一人受试者的至少两种样品的早期生物标记物帮助超急性诊断确定创伤性脑损伤的方法
WO2018218169A1 (en) 2017-05-25 2018-11-29 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
WO2018222783A1 (en) 2017-05-30 2018-12-06 Abbott Laboratories Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin i and early biomarkers
JP2020522701A (ja) 2017-06-02 2020-07-30 ザ・ジョンズ・ホプキンス・ユニバーシティ パーキンソン病患者のｃｓｆ中のｐａｒの検出
EP3631448A4 (en) * 2017-06-02 2021-03-03 The Johns Hopkins University DETECTION OF PAR IN THE CSF OF PATIENTS WITH PARKINSON'S DISEASE
ES2993181T3 (en) * 2017-06-19 2024-12-23 St Johns Univ Circulating serum microrna biomarkers and methods for determining the progression rate of parkinson's disease
EP3649474A1 (en) 2017-07-03 2020-05-13 Abbott Laboratories Improved methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood
EP3700556A2 (en) 2017-10-25 2020-09-02 Janssen Pharmaceuticals, Inc. Compositions of phosphorylated tau peptides and uses thereof
JP6942036B2 (ja) * 2017-11-30 2021-09-29 藤倉化成株式会社 脳梗塞の発症リスクを高感度に検出する体液抗体バイオマーカー
US11016105B2 (en) 2017-12-09 2021-05-25 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of GFAP and UCH-L1
EP3721233A2 (en) 2017-12-09 2020-10-14 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
AU2018395255B2 (en) 2017-12-29 2025-02-20 Abbott Laboratories Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury
KR102026675B1 (ko) * 2018-02-12 2019-09-30 강원대학교산학협력단 miR-135a-5p 및 p62에 의한 알레르기 반응 조절 메커니즘 및 이의 이용
CA3265017A1 (en) * 2018-03-08 2025-10-31 Meso Scale Technologies, Llc. Genetic marker and/or biomarkers for traumatic brain injury, and ultrasensitive assays for biomarkers of traumatic brain injury
JP6499342B2 (ja) * 2018-03-19 2019-04-10 隆樹 日和佐 脳梗塞の診断マーカー
WO2019207159A1 (en) * 2018-04-27 2019-10-31 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
WO2020023789A2 (en) * 2018-07-25 2020-01-30 Srnalytics, Inc. Small rna predictors for alzheimer's disease
CN110824156B (zh) * 2018-08-14 2023-08-11 欧蒙医学诊断（中国）有限公司 神经自身免疫疾病的诊断
WO2020037311A1 (en) * 2018-08-17 2020-02-20 University Of Florida Research Foundation, Inc. Protein and peptide biomarkers for traumatic injury to the central nervous system
CN113195740A (zh) * 2018-10-17 2021-07-30 奥克斯纳健康系统公司 在脑内出血和蛛网膜下腔出血中的血浆和脑脊液miRNA生物标志物
CN109266739A (zh) * 2018-11-29 2019-01-25 成都仕康美生物科技有限公司 一种检测脑损伤的miRNA标志物、试剂盒、应用
EP3891295B1 (en) * 2018-12-04 2026-03-25 La Trobe University Methods of diagnosing a disease state
MY206596A (en) 2019-02-08 2024-12-25 Janssen Pharmaceuticals Inc Method of safe administration of phosphorylated tau peptide vaccine
EP4578961A3 (en) * 2019-02-14 2025-12-24 Marker Diagnostics UK Limited Salivary biomarkers of brain injury
GB201909393D0 (en) * 2019-06-28 2019-08-14 Gen2 Neuroscience Ltd Tau epitope and binding molecules
CN110551809A (zh) * 2019-08-21 2019-12-10 昆明医科大学第一附属医院 miR-124在脊髓损伤修复中的用途
US11644463B2 (en) * 2019-08-30 2023-05-09 Euroimmun Medizinische Labordiagnostika Ag Detection of an autoantibody
WO2022011269A2 (en) * 2020-07-09 2022-01-13 University Of Florida Research Foundation, Incorporated Biofluid-based protein and mirna biomarkers for neonatal hypoxic-ischemic encephalopathy
MX2023002237A (es) * 2020-08-24 2023-05-25 Marabio Systems Inc Metodos para reducir los anticuerpos maternales.
KR102357260B1 (ko) * 2020-12-10 2022-02-08 주식회사 레피겐엠디 마이크로rna를 이용한 당뇨병성 신경병증의 예측 및 진단 방법 및 이를 위한 키트
CN113238045B (zh) * 2021-04-27 2021-12-28 南方医科大学南方医院 Crmp2及抗crmp2抗体的应用
KR102759445B1 (ko) * 2021-11-16 2025-01-24 한국한의학연구원 치료에 따른 보행 장애 개선 판별용 바이오마커 및 이의 용도
US20240212139A1 (en) * 2022-12-22 2024-06-27 National Taiwan University Automatic calculation method of gray-to-white-matter ratio for head computed tomography of patients with cardiac arrest
WO2025235699A1 (en) * 2024-05-08 2025-11-13 Owi Therapeutics Llc Astrocytic monomeric, oligomeric, or aggregate breakdown products of glial fibrillary acidic protein

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
CA2084987C (en) 1990-06-11 2007-02-13 Gilead Sciences, Inc. Nucleic acid ligands
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5683867A (en) 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5707796A (en) 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
EP0600951A4 (en) * 1991-08-01 1996-10-30 Paul H Voorheis Diagnostic method for alzheimer's disease.
US5731410A (en) 1994-11-28 1998-03-24 University Of Utah Research Foundation Peptide for blocking autoantibody-evoked activation of glutamate receptor type 3 (GLUR3)
JP4624559B2 (ja) * 1998-09-08 2011-02-02 イノジェネティックス・ナムローゼ・フェンノートシャップ 初期ｃｎｓダメージのマーカーとしてのタウ
US20020002270A1 (en) 1999-06-16 2002-01-03 Raymond P. Zinkowski Purified antigen for alzheimer's disease, and methods of obtaining and using same
US6589746B1 (en) * 1999-10-21 2003-07-08 University Of Cincinnati Method of detecting axonally-derived protein tau in patients with traumatic CNS injury
US7713705B2 (en) 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US20030199000A1 (en) 2001-08-20 2003-10-23 Valkirs Gunars E. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US20040203083A1 (en) 2001-04-13 2004-10-14 Biosite, Inc. Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases
US20040253637A1 (en) 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US20020172676A1 (en) * 2001-05-16 2002-11-21 George Jackowski Method of treatment of alzheimer's disease and device therefor
US7144708B2 (en) 2001-06-25 2006-12-05 The Cleveland Clinic Foundation Markers of blood barrier disruption and methods of using same
JP2005522669A (ja) 2001-08-20 2005-07-28 バイオサイト インコーポレイテッド 卒中および脳損傷の診断マーカーおよびその使用方法
AU2002329570A1 (en) 2001-10-12 2003-01-30 Pfizer Products Inc. Method of monitoring neuroprotective treatment
AU2003243563A1 (en) 2002-06-12 2004-09-28 The Cleveland Clinic Foundation Markers of blood barrier permeability and methods of using same
WO2004025298A1 (en) 2002-09-11 2004-03-25 University Of Florida Analyzing nerve cell damage
AU2003302340B8 (en) 2002-12-24 2008-09-11 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
CA2532130C (en) 2003-09-20 2016-07-19 Electrophoretics Limited Diagnostic method for brain damage-related disorders
EP1519194A1 (en) 2003-09-24 2005-03-30 Roche Diagnostics GmbH Use of gfap for identification of intracerebral hemorrhage
JP4885122B2 (ja) * 2004-04-15 2012-02-29 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 癌、器官傷害、および筋肉リハビリテーション／運動過剰訓練についての診断の生物マーカーとしてのタンパク質分解マーカー
US8492107B2 (en) 2004-04-15 2013-07-23 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
US20140303041A1 (en) 2004-04-15 2014-10-09 University Of Florida Research Foundation Inc. In vitro diagnostic devices for nervous system injury and other neural disorders
US7396654B2 (en) 2004-04-15 2008-07-08 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for traumatic brain injury
GB2428240A (en) * 2005-07-14 2007-01-24 Univ Gen Ve Diagnostic method for brain damage-related disorders
WO2007046811A2 (en) 2005-10-20 2007-04-26 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
EP1992688B1 (en) 2006-02-15 2016-06-22 Mie University Method of constructing recombinant proteoliposome for diagnostic use
WO2007136617A2 (en) * 2006-05-18 2007-11-29 Walter Reed Army Institute Of Research (Wrair) Endothelial-monocyte activating polypeptide ii, a biomarker for use in diagnosis of brain injury
EP2024395A4 (en) 2006-05-26 2009-07-01 Biosite Inc USE OF NATRIURETIC PEPTIDES AS DIAGNOSTIC AND PROGNOSTIC INDICATORS IN VASCULAR DISEASES
CN101983337A (zh) 2008-02-04 2011-03-02 班扬生物标记公司 用于诊断或治疗脑损伤的方法
EP2143735A1 (en) 2008-07-10 2010-01-13 Institut Pasteur Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
US20140342381A1 (en) 2008-08-11 2014-11-20 Banyan Biomarkers, Inc. Devices and methods for biomarker detection process and assay of neurological condition
CA2733990C (en) * 2008-08-11 2018-12-11 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
US20120094295A1 (en) 2008-11-21 2012-04-19 The Johns Hopkins University Neurodegenerative disease diagnostic compositions and methods of use
CA2766057A1 (en) * 2009-06-19 2010-12-23 Banyan Biomarkers, Inc. Biomarker assay of neurological condition
US20170315136A9 (en) 2009-06-19 2017-11-02 Banyan Biomarkers, Inc. Biomarker assay of neurological condition
US20120202231A1 (en) 2009-07-18 2012-08-09 Kevin Ka-Wang Wang Synergistic biomarker assay of neurological condition using s-100b
WO2011032155A2 (en) 2009-09-14 2011-03-17 Banyan Biomarkers, Inc. Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury
CA2809737A1 (en) 2010-04-01 2011-10-06 Banyan Biomarkers, Inc. Markers and assays for detection of neurotoxicity
WO2011160096A2 (en) 2010-06-17 2011-12-22 Banyan Biomarkers, Inc. Glial fibrillary acidic protein, autoantigens and autoantibodies thereto as biomarkers of neural injury or neurological disorder or condition
CN108593926A (zh) 2011-09-14 2018-09-28 促进军事医学的亨利·M·杰克逊基金会公司 检测和监测用于ptsd的诊断生物标志物以及区分自杀式与非自杀式障碍的方法和试剂盒
US20140024053A1 (en) 2012-07-20 2014-01-23 Banyan Biomarkers, Inc. Methods, kits and devices for detecting bii-spectrin, and breakdown products thereof, as biomarkers for the diagnosis of neural injury
US20140275294A1 (en) 2013-03-15 2014-09-18 Banyan Biomarkers, Inc. Devices and methods for biomarker detection process and assay of liver injury
WO2014194329A1 (en) 2013-05-31 2014-12-04 Banyan Biomarkers, Inc. NEURAL SPECIFIC S100β FOR BIOMARKER ASSAYS AND DEVICES FOR DETECTION OF A NEUROLOGICAL CONDITION

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103656685A (zh) * 2014-01-10 2014-03-26 厦门大学 microRNA-219在制备抗癫痫药物中的应用

Also Published As

Publication number Publication date
US20170242041A1 (en) 2017-08-24
JP2017181518A (ja) 2017-10-05
WO2011032155A2 (en) 2011-03-17
AU2010291933B2 (en) 2016-09-08
US20190064188A1 (en) 2019-02-28
EP2478360A4 (en) 2013-04-03
EP2478360A2 (en) 2012-07-25
JP2013504331A (ja) 2013-02-07
WO2011032155A3 (en) 2011-10-06
AU2010291933A1 (en) 2012-05-10
JP6469760B2 (ja) 2019-02-13
US20130022982A1 (en) 2013-01-24
JP5909447B2 (ja) 2016-04-26
JP2016105097A (ja) 2016-06-09
AU2016269481A1 (en) 2016-12-22
EP2478360B1 (en) 2018-06-27
HUE040281T2 (hu) 2019-03-28
ES2687469T3 (es) 2018-10-25
AU2016269481B2 (en) 2018-08-30
US10041959B2 (en) 2018-08-07

Similar Documents

Publication Publication Date Title
US10041959B2 (en) Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury
AU2011235892B2 (en) Markers and assays for detection of neurotoxicity
EP3336551B1 (en) Biomarker detection process and assay of neurological condition
US20150268252A1 (en) Biomarker assay of neurological condition
EP3355059A2 (en) Biomarker assay of neurological condition
US20160102354A1 (en) Systems For Biomarker Detection
EP3115785A2 (en) Process to diagnose or treat brain injury
WO2011160096A2 (en) Glial fibrillary acidic protein, autoantigens and autoantibodies thereto as biomarkers of neural injury or neurological disorder or condition
US20200103419A1 (en) Blood biomarkers and diagnostic methods for small vessel diseases
WO2015134551A1 (en) Micro rna markers for diagnosis of a neurological condition
US10718029B2 (en) Treatment targeting oncology and neurodegeneration
ES2310057B1 (es) Metodo de analisis molecular y tratamiento en demencia de cuerpos de lewy.
JP6338872B2 (ja) 視神経障害発症リスクの判定方法
KR102202120B1 (ko) 알츠하이머 질환의 진단 또는 치료를 위한 Ｕｂｅ２ｈ의 용도
Soto Gimeno Uncovering novel biomarkers for Parkinson’s disease and its prodromal stages
US7879568B2 (en) Method for the diagnosis and prognosis of demyelinating diseases
Garmy et al. Cellular isoform of the prion protein PrPc in human intestinal cell lines: Genetic polymorphism at codon 129, mRNA quantification and protein detection in lipid rafts
EP2532755A1 (en) Methods and uses based on Slfn2 expression and relating to the identification and profiling of compounds for use in the treatment or prevention of pain

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150911

FZDE Dead

Effective date: 20200916